DOCSLIB.ORG

Annual Meeting 2020 Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

INCORPORATING JOINT STUDY DAY Platinum Sponsor WITH CYSTIC FIBROSIS TRUST FRIDAY 31ST JANUARY 2020 E&OE ANNUAL MEETING 2020 WEDNESDAY 29TH – FRIDAY 31ST JANUARY. THE DOME, CHURCH STREET, BRIGHTON ABSTRACTS Brighton Dome Thanks to all of our sponsors On behalf of BSPGHAN and the local organisers in Brighton, we are sincerely most grateful to all our partners for their contributions to the Annual Meeting. Our commercial sponsors and charitable organisations play an integral part in our meeting to complement the independently developed scientific programme. This interaction provides the opportunity to share and acquire knowledge in partnership for the mutual benefit of patient care. We are pleased to welcome established and new sponsors to our 2020 meeting providing some continuity but also variety with opportunity for new dialogue. Informed dialogue and open exchange of information are of key importance; it is with this spirit, that we encourage all delegates to take time to visit the exhibitors and to thank them for their continued support of our annual BSPGHAN events. ANNUAL MEETING BSPGHAN PLATINUM SPONSOR SILVER SPONSOR BRONZE SPONSORS POSTER IBD AWARD Dr Falk 29TH - 31ST JAN 2020 CHARITIES Children’s Liver Disease Foundation CICRA GUTS UK SPONSORED SYMPOSIA BSPGHAN Abstract Book Index: Plenary Abstracts: Session I Wednesday P3 Session II Thursday P11 Session III Friday P23 Posters selected for: BSPGHAN Best Poster Award P32 Dr Falk IBD Award P105 BSPGHAN Annual Meeting 29th – 31st January 2020, Brighton Abstracts RCPCH has approved this activity for CPD in accordance with the current RCPCH CPD Guidelines 1 Wednesday 29th January 2020 Plenary Session I Oral Abstract Presentations BSPGHAN Annual Meeting 29th – 31st January 2020, Brighton Abstracts RCPCH has approved this activity for CPD in accordance with the current RCPCH CPD Guidelines 2 12.10 – 12.20 Nabilone for Gastrointestinal Dystonia. A single centre case series Miss Michelle Brooks1, Dr Joseph Symonds2, Miss Sarah Bremner3, Dr Victoria Merrick1, Dr Diana Flynn1, Miss Christina McGuckin1, Mr Simon Fraser4, Miss Karen Fraser5, Mr Gregor Walker6, Mr James Andrews6, Mr Timothy Bradnock6, Dr Andreas Brunklaus2, Dr Katharine Forrest2, Dr Valerie Orr7 and Andrew Barclay1. 1Paediatric Gastroenterology, Royal Hospital for Children, Glasgow UK; 2Paediatric Neurology, Royal Hospital for Children, Glasgow UK;3Paediatric Dietetics, Royal Hospital for Children, Glasgow, UK; 4Paediatric Pharmacy, Royal Hospital for Children, Glasgow, UK; 5Admin Services, Royal Hospital for Children, Glasgow, UK;6Paediatric Surgery, Royal Hospital for Children, Glasgow, UK;7Paediatric Neurodisability, Royal Hospital for Children, Glasgow, UK In severe neurodisabling conditions the clinical constellation of pain behaviour, retching, bloating, abdominal distension and constipation/pseudo-obstruction can be referred to as gastrointestinal dystonia (GID)(1).The evidence base for effective therapies are very limited (1) and symptoms can remain disabling. Nabilone a synthetic analogue of the active component tetrahydrocannabinol (THC) found in cannabis has a licence in paediatrics for the treatment of severe chemotherapy induced nausea, however, as medical cannabis has also been implicated in the treatment of pain, spasticity, gastrointestinal upset and apetite stimulation, it has been hypothesised as a potential agent to treat GID. To date we are unaware of any published work reporting the use of Nabilone in GID. We aimed to describe our experience of using nabilone for patients with GID. Approval was sought on a named patient basis from the clinical directorate and head pharmacist on the basis that; patients fulfilled our criteria for GID (1), patients had been trialled on medical therapies, jejunal feeding and blended diet, concomittant medication reviewed in MDT including tone management and to review potential exacerbants to GID, all members of MDT were in agreement that trial of treatment was warranted. Patients were admitted for 48hrs of documentation of symptoms using modified paediatric pain score. TPR and overnight saturations were peformed pre and post treatment for 48hrs. With the potential for pre-existing neuro- respiratory depression, Nabilone was commenced below previously described paediatric dosing and then incremented in 250ug doses to a dosage of <18kgs: 500ug bd and 18-27kg: 500ug tds. Efficacy was assessed by parents and clinicians perception, PedsQL ver 3.0 (GI questions) and sleep diary, all performed prior to treatment and one month after stable dose. Global Peds QL scores analysed by paired student's t-test (p<0.05). 3 patients were treated - all male, 2.4-9yrs, 10.5-18kg, 2 cerebral palsy and 1 undiagnosed condition. Parents and clinicians perceptions were that treatment had improved symptoms. All patients had an increase in their Peds QL scores post treatment. Most significant increase in median scores were in the domains 'stomach discomfort when feeding' (5 to 85 (p<0.006)) and 'nausea and vomiting' (6.25 to 56.25 (P=0.02)). The patient with sleep disturbance was awoken a median of 3 times pre to once per night on treatment. Nabilone shows promise in treating GID , a poorly understood debilitating complication of severe neurodisability, in particular, symptoms of nausea and retching. Of note, two patients were being considered for parenteral nutrition for nutritional failure. Further evaluation of this treatment is warranted in clinical trials or on a further named patient basis. The authors advocate a wide MDT setting, with input from Gastroenterology, Surgery and Neurodisability. We currently reserve this for refractory patients for whom most known measures have been ineffective. The authors also note that the current objective tools have limitations in capturing efficacy of interventions for GID due to diffuse and complex symptoms. Future study would be aided by the existence of a specific assessment tool for symptomatology. 1. McConnell N, Beattie LM, Richards CE, Protheroe S, Barclay AR,JPGN;66 (supp 2):1002;2018 BSPGHAN Annual Meeting 29th – 31st January 2020, Brighton Abstracts RCPCH has approved this activity for CPD in accordance with the current RCPCH CPD Guidelines 3 12.20 – 12.30 Children and young people with inflammatory bowel disease attend less school than their healthy peers Claire Barnes1, James Ashton1, Florina Borca2, Mick Cullen1, Dawn Walker3 and Robert Beattie1. 1University Hospital Southampton 2 3 NIHR Southampton Biomedical Research Centre; University of Southampton Aim: Chronic diseases, such as inflammatory bowel disease (IBD), can impact negatively on education and social development. The aim of this study is to examine the extent to which IBD affects school/college attendance for children and young people (CYP) and determine contributing factors. Methods: We performed a cross-sectional survey to determine the school/college attendance rates, the reasons for absence related to IBD and facilitators/barriers to school/college attendance. In a subset followed-up locally, we performed a detailed review of hospital attendance data, to assess the healthcare burden. Results: Two-hundred-and-thirty-one questionnaires were given to CYP with IBD aged 5-17 years. The response rate was 74% (final sample 169). The median school/college attendance rate was 92.5%; significantly lower than all children in England (95.2%). 39.6% of children with IBD were persistently absent, defined nationally as missing 10% or more of school. Only five children (3%) had a 100% attendance record. Increasing age and use of monoclonal therapy were predictors of poor school attendance. Concerns about feeling unwell at school/college, access to toilets, keeping up with work, and teachers’ understanding of IBD are the main issues for CYP with IBD. (This is highlighted in the word cloud - figure 1, illustrating the questionnaire free text comments). There was a significant negative correlation between number of days in hospital and school attendance. Conclusion: IBD has a significant impact on school/college attendance, with hospital attendance, disease burden, and school difficulties being major factors. Employing strategies to minimise healthcare burden and developing a partnership between health and education, to support children with IBD will serve to facilitate school/college attendance. Figure 1 – Word cloud of questionnaire free text comments A graphical representation of word frequency from the questionnaire free text comments. The size of the word indicates its frequency; the more often a word appears in the text the bigger and bolder it appears in the word cloud. BSPGHAN Annual Meeting 29th – 31st January 2020, Brighton Abstracts RCPCH has approved this activity for CPD in accordance with the current RCPCH CPD Guidelines 4 12.30 – 12.40 D1 biopsies increases the diagnostic yield in coeliac disease in children Chloe Ashton1, Jeng Cheng1 and Veena Zamvar1. 1 Leeds Teaching Hospitals Introduction/Background: Coeliac disease is an autoimmune systemic condition, which is triggered by gluten in genetically predisposed patients. These patients are genetically predisposed to HLA markers DQ2 or DQ8. Coeliac disease can present in children with gastrointestinal symptoms, failure to thrive and dermatitis herpetiformis; and can be asymptomatic especially in high-risk individuals such as children with Down’s syndrome, Type 1 diabetes and Turner’s syndrome. Children who are symptomatic, are recommended to undergo total immunoglobulin A (IgA), tissue transglutaminase (TTG) and
Recommended publications
  • Comparison of the Rome IV Criteria with the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care

    Comparison of the Rome IV Criteria with the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care

    This is a repository copy of Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/166989/ Version: Accepted Version Article: Black, CJ, Craig, O, Gracie, DJ et al. (1 more author) (2020) Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. ISSN 0017-5749 https://doi.org/10.1136/gutjnl-2020-322519 © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This manuscript version is made available under the CC BY-NC 4.0 license https://creativecommons.org/licenses/by-nc/4.0/ Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative works on the same terms. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Black et al. Page 1 of 38 Accepted for publication 3rd September 2020 TITLE PAGE Title: Comparison of the Rome IV Criteria with the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care.
  • Editorial BURRILL BERNARD CROHN (1884-1983): the MAN

    Editorial BURRILL BERNARD CROHN (1884-1983): the MAN

    ABCDDV/967 ABCD Arq Bras Cir Dig Editorial 2013;26(4):253-255 BURRILL BERNARD CROHN (1884-1983): THE MAN BEHIND THE DISEASE Burrill Bernard Crohn (1884-1983): o homem por trás da doença Fábio Guilherme M. C. de CAMPOS1 e Paulo Gustavo KOTZE2 1Colorectal Surgery Division, Gastroenterology Department. Hospital das Clínicas, University of São Paulo Medical School, Brazil; 2Colorectal Surgery Unit, Cajuru University Hospital, Catholic University of Paraná, Curitiba, PR, Brazil urrill Bernard Crohn was born in June 13th, my professional life as a student of constipation and 1884, in the city of New York. From a family diarrhea. Sometimes I could wish to have chosen ear, of jewish emigrants from Europe, Theodore nose and throat as a specialty rather than the tail end B 3 and Leah Crohn had 12 children, educated as Jewish of the human anatomy…” . orthodoxy, still spread over the generations5. Gastroenterologists existed much earlier than In New York, he attended City College (Class of gastroenterology was recognized, and defined as 1902) where his interest for the medical career was one of the internal medicine’s specialties. That was born. According to his own biography, he decided to what happened with Crohn, as most of the digestive follow the medical pathway because his father used to diseases wards were in held of surgeons at that time. have terrible digestion problems; so, he chose to help He was only recognized as a full member of the him by studying medicine. He received his medical American Gastroenterological Association (AGA) in degree at Columbia University’s College of Physicians 1917, mentored and helped by William J.
  • An Investigation Into the Role of Optineurin in Macrophage-Mediated Acute Antibacterial Response in Inflammatory Bowel Disease

    An Investigation Into the Role of Optineurin in Macrophage-Mediated Acute Antibacterial Response in Inflammatory Bowel Disease

    An investigation into the role of optineurin in macrophage-mediated acute antibacterial response in inflammatory bowel disease By Thean Soon Chew A thesis submitted to UCL for the degree of Doctor of Philosophy Division of Medicine 2015 1 I, Thean Soon Chew confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 ex nihilo nihil fit 3 Abstract Crohn’s disease (CD) is now recognised to be due to defective host responses to bacteria in genetically susceptible individuals. Others in our research group previously found defective neutrophil recruitment, bacterial clearance and monocyte-derived macrophage (MDM) proinflammatory cytokine secretion in CD. To investigate the defective cytokine secretion, we performed transcriptomic analysis and identified reduced MDM optineurin (OPTN) expression in 10% CD patients. Here, I show that macrophages stimulated with E. coli, bacterial Toll-like and NOD-like receptor ligands upregulate OPTN, a Golgi complex protein that regulates vesicle transport. In vitro, Optn-/- bone marrow-derived macrophages (BMDM) stimulated with E. coli secrete significantly lower levels of proinflammatory TNF and IL6 cytokines, which is normalised to wildtype levels on addition of lysosomal function inhibitors. In vivo, Optn-/- mice develop a more severe Citrobacter colitis with greater mortality, an early defective neutrophil recruitment to the bowel and lower levels of serum proinflammatory cytokines. The Optn-/- mice also demonstrated a similar phenotype of defective neutrophil recruitment and lower serum proinflammatory cytokines in an E. coli-induced peritonitis. These results indicate that the low OPTN expression originally identified in CD macrophages has likely contributed to an attenuated antibacterial response, which potentially led to the development of bowel inflammation.
  • Ulcerative Colitis

    Ulcerative Colitis

    F1000Research 2020, 9(F1000 Faculty Rev):294 Last updated: 27 APR 2020 REVIEW Ulcerative colitis: Recent advances in the understanding of disease pathogenesis [version 1; peer review: 2 approved] Ross J Porter , Rahul Kalla, Gwo-Tzer Ho Edinburgh IBD Science Unit, Centre for Inflammation Research, Queens Medical Research Unit, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK First published: 24 Apr 2020, 9(F1000 Faculty Rev):294 Open Peer Review v1 https://doi.org/10.12688/f1000research.20805.1 Latest published: 24 Apr 2020, 9(F1000 Faculty Rev):294 https://doi.org/10.12688/f1000research.20805.1 Reviewer Status Abstract Invited Reviewers Inflammatory bowel diseases are common, complex, immune-mediated 1 2 conditions with a sharply rising global prevalence. While major advances since 2000 have provided strong mechanistic clues implicating a version 1 de-regulation in the normal interaction among host genetics, immunity, 24 Apr 2020 microbiome, and the environment, more recent progress has generated entirely new hypotheses and also further refined older disease concepts. In this review, we focus specifically on these novel developments in the pathogenesis of ulcerative colitis. F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are Keywords Ulcerative colitis, Inflammatory Bowel Disease, Inflammation, Mucosal commissioned and are peer reviewed before Immunology, Pathogenesis publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. 1 Jonathan Rhodes, University of Liverpool, Liverpool, UK 2 Barney Hawthorne, University Hospital of Wales, Cardiff, UK Any comments on the article can be found at the end of the article.
  • The Impact of Vitamin D on Disease Activity in Crohn’S Disease

    The Impact of Vitamin D on Disease Activity in Crohn’S Disease

    THE IMPACT OF VITAMIN D ON DISEASE ACTIVITY IN CROHN’S DISEASE A Thesis Submitted to the College of Graduate Studies and Research in Partial Fulfillment of the Requirements for the Degree Masters of Science in the College of Pharmacy and Nutrition Division of Nutrition and Dietetics University of Saskatchewan Saskatoon, Canada By Dania Ahmed Alrefai © Copyright Dania Ahmed Alrefai, February, 2015. All rights reserved. PERMISSION TO USE In presenting this thesis in partial fulfillment of the requirements for a Master degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor who supervised my thesis work: Dr. Hassanali Vatanparast, M.D. Ph.D. Associates Professor, College of Pharmacy and Nutrition In his absence, permission may be granted by the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis. Requests for permission to copy or to make other use of material in this thesis in whole or part should be addressed to: Dean of the College of Pharmacy and Nutrition E3122 - 104 Clinic Place University of Saskatchewan Saskatoon, SK, Canada S7N 2Z4 i ABSTRACT Canada has the highest rate of Inflammatory Bowel Disease (IBD) in the world with approximately 0.67%.
  • Supplementary Tables and Appendices

    Supplementary Tables and Appendices

    BSG IBD guidelines 2019: Supplementary tables and appendices BSG guidelines 2019: Supplementary tables and appendices Supplementary Table 1: Affiliations of IBD guidelines eDelphi consensus group ....................................................................................................... 2 Supplementary Table 2: Conflicts of interests declared by guideline development group at time of submission for publication and prior to final eDelphi vote for all other contributors ........................................................................................................................................................................ 6 Supplementary Table 3: Number of voters and abstentions for Statements and Good Practice Recommendations in final eDelphi vote ............ 22 Supplementary Table 4: Readability testing of research priority themes derived from systematic review ............................................................. 24 Supplementary Table 5: Subgroup analyses of research theme importance to respondents of 1st and 2nd survey by Crohn’s and Colitis UK ....... 25 Supplementary Appendix 1: Clinical question development mapped to clinical framework ................................................................................... 26 Supplementary Appendix 2: Systematic review database search strategy ............................................................................................................... 52 Supplementary Appendix 3: Statements failing to reach 80% consensus agreement in final eDelphi
  • British Society of Gastroenterology and UK-PSC Guidelines for the Diagnosis and Management of Gut: First Published As 10.1136/Gutjnl-2018-317993 on 1 June 2019

    British Society of Gastroenterology and UK-PSC Guidelines for the Diagnosis and Management of Gut: First Published As 10.1136/Gutjnl-2018-317993 on 1 June 2019

    Guidelines British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of Gut: first published as 10.1136/gutjnl-2018-317993 on 1 June 2019. Downloaded from primary sclerosing cholangitis Michael Huw Chapman, 1,2 Douglas Thorburn,2 Gideon M Hirschfield,3 George G J Webster,1 Simon M Rushbrook,4 Graeme Alexander,2 Jane Collier,5 Jessica K Dyson,6,7 David EJ Jones,7 Imran Patanwala,8,9 Collette Thain,10 Martine Walmsley,11 Stephen P Pereira1,12 1GI Division, UCL Hospitals NHS ABSTRact cholangiocarcinoma (CCA). Patients with PSC Foundation Trust, London, UK 2 These guidelines on the management of primary should ordinarily not undergo endoscopic retro- Liver Unit, Royal Free London grade cholangiopancreatography (ERCP) until NHS Foundation Trust, London, sclerosing cholangitis (PSC) were commissioned by UK the British Society of Gastroenterology liver section. there has been expert multidisciplinary assessment 3Toronto Centre for Liver The guideline writing committee included medical to justify endoscopic intervention. Colitis should be Disease, University Health representatives from hepatology and gastroenterology sought in all patients with PSC using colonoscopy Network and University of groups as well as patient representatives from PSC and colonic biopsies. Patients with colitis should Toronto, Toronto, Canada 4Department of Hepatology, Support. The guidelines aim to support general then have annual surveillance colonoscopy because Norfolk and Norwich University physicians, gastroenterologists and surgeons in of the increased risk of colorectal cancer. In these Hospitals NHS Trust, Norwich, managing adults with PSC or those presenting with guidelines, we also review the management of PSC UK similar cholangiopathies which may mimic PSC, such as overlap syndromes and IgG4-related sclerosing 5Hepatology, John Radcliffe Hospital, Oxford, UK IgG4 sclerosing cholangitis.